Primary analysis of a randomised, placebo-controlled phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2018
This article has no abstract
Epistemonikos ID: e1aa1fc6252c86afeb87fa820abf58728945653f
First added on: Apr 30, 2026